

Georgia

COUNTRY GENERAL INFORMATION

Total population:	4 002 946
Gender F/M (%):	52.3 / 47.7
Population, age group <15 / ≥ 15 years (%):	20 / 80
Life expectancy at birth (F/M, years):	77 / 68
GDP (PPP int \$):	11 421
Income status:	Upper middle income
Number of 2 nd sub-national administrative level divisions, name:	72, Municipality


EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	52	0	0	0
Number of relapses: ¹	2	0	N/A	N/A
Total number of cases:	54	0	0	0
Imported cases (#, %):	0, 0%	0	N/A	N/A
Gender distribution (% F):	42	N/A	N/A	N/A
Age group distribution (% <5 / 5-14 / >14):	58 / 11 / 31	N/A	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.21	0	N/A	N/A
Number of endemic 2 nd sub-national administrative level divisions:	21	No data	N/A	N/A
Population at risk (% # at risk / total population): ²	65% 2 621 000 / 4 002 946	0% 0 / 4 002 946	N/A	N/A
Was there any outbreak?	Yes	No	N/A	N/A
Number of new foci: ³	4	0	N/A	N/A



Monthly distribution of new cases (January-December)

2018	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	8	4	3	3	3	5	8	3	3	5	1	6
CL	0	0	0	0	0	0	0	0	0	0	0	0

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and incidence rate/10,000 at the national level from 2003 to 2018




¹ Relapse in this country is defined as: For VL "Recurrence of clinical signs or symptoms of VL with parasitological confirmation, after initial or clinical cure" and For CL: "Recurrence of skin lesion on the same location confirmed by parasitological investigation after completion of treatment"

² Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

³ Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL cases at Municipality level per 10,000 population (2018)⁴



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	No LNCP
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	Synthetic pyrethroids
Year latest national guidelines (CL / VL):	2009 / 2009
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	52 / 52

DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	351	0	N/A	N/A
Number of people screened passively for:	252	2	N/A	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	67% (35/52)	N/A	N/A	N/A
Proportion of positive RDT (% , # slides + / total RDT):	14% (35/252)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	29% (15/52)	0	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	43% (15/35)	N/A	N/A	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/54)	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	2% (1/54)	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	98% (51/52)	N/A
Initial cure rate (% , # cases initially cured / new cases):	98% (51/52)	N/A
Failure rate (% , # cases with treatment failure / new cases): ⁵	0% (0/52)	N/A
Case fatality rate (% , # cases who died / new cases): ⁶	1.9% (1/52)	N/A

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴Municipalities appearing transparent on the map are non-endemic.

⁵Failure in this country is defined as: "clinical signs and laboratory findings do not improve or worsen by the end of treatment course"

⁶The patient died before administrating any therapeutic option.